DEF 14A: Revvity, Inc. Announces Details for 2024 Annual Shareholder Meeting
Proxy Statement
Revvity, Inc. has released its proxy statement detailing proposals for the upcoming 2024 annual meeting of shareholders, including the election of directors, ratification of the company's accounting firm, and an advisory vote on executive compensation.
Summary
- Revvity, Inc. will hold its 2024 annual meeting of shareholders on April 23, 2024, via live webcast.
- Shareholders of record as of February 26, 2024, are entitled to vote on several proposals.
- The proposals include the election of ten directors, ratification of Deloitte & Touche LLP as the independent registered public accounting firm, an advisory vote on executive compensation, and a shareholder proposal regarding simple majority voting.
- The board of directors recommends voting FOR the election of directors, FOR the ratification of Deloitte & Touche LLP, FOR the advisory vote on executive compensation, and AGAINST the shareholder proposal regarding simple majority voting.
- In 2023, Revvity had GAAP earnings per share from continuing operations of $1.44 and adjusted earnings per share from continuing operations of $4.65.
- GAAP revenue for 2023 was $2,751 million, and GAAP operating income from continuing operations was $301 million.
- The company is focused on developing employees' talents, supporting their well-being, fostering a diverse and inclusive culture, and engaging employees to achieve a shared vision.
- Revvity is committed to environmental, social, and governance (ESG) principles, including setting emission reduction targets, creating sustainability committees, and promoting pay equity.
Sentiment
Score: 6
Explanation: The document presents a mix of positive and negative information. While the company highlights its commitment to ESG principles and employee development, it also acknowledges a decline in key financial metrics. The overall sentiment is neutral to slightly positive.
Positives
- The company is focused on developing employees' talents through multiple corporate and personalized AI-powered programs promoting learning, career growth and recognition structure for all employees within the Company.
- The company is supporting the well-being of its employees.
- The company is offering a diverse and inclusive culture aligned with its values.
- The company is engaging its employees to achieve a shared vision of an innovative and inclusive future.
- The company is growing a culture of sustainability through educating and empowering its employees.
- The company is expanding its equity and inclusion communities on a global, regional and local level.
- The company is investing in programs and tools that advance the talent management and professional development opportunities for its people.
- The company is committing to promoting pay equity within its organization through conducting pay audits and benchmarking.
Negatives
- GAAP earnings per share from continuing operations decreased from $4.06 in 2022 to $1.44 in 2023.
- Adjusted earnings per share from continuing operations decreased from $6.92 in 2022 to $4.65 in 2023.
- GAAP revenue decreased from $3,312 million in 2022 to $2,751 million in 2023.
- GAAP operating income from continuing operations decreased from $743 million in 2022 to $301 million in 2023.
- GAAP operating profit margin from continuing operations decreased from 22.4% in 2022 to 10.9% in 2023.
Risks
- The document mentions industrywide headwinds that impacted financial results in 2023.
- The company's future performance is subject to evolving macro environment.
Future Outlook
The company believes that its strategic priorities, expanded range of product offerings, leading market positions, global scale, financial strength, and strong culture provide a foundation for continued revenue growth, strong margins and cash flows, and long-term earnings per share growth.
Management Comments
- Our performance in the face of an evolving macro environment is both a testament to the hard work of our incredible team and the result of the transformation that has taken place at our Company in recent years, not only from a portfolio composition standpoint, but also from an operational agility and collaboration perspective.
Industry Context
The document mentions industrywide headwinds that impacted financial results in 2023, suggesting that other companies in the same industry may have faced similar challenges.
Comparison to Industry Standards
- The document compares Revvity's executive compensation to a peer group of companies including Agilent Technologies, Inc., Bruker Corporation, Hologic, Inc., The Cooper Companies, Inc., Avantor, Inc., Catalent, Inc., Illumina, Inc., Thermo Fischer Scientific Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, QIAGEN N.V., Waters Corporation, Bio-Techne Corporation, Exact Sciences Corporation, and QuidelOrtho Corporation.
- The median revenue of the peer group at the time it was approved was $3,380 million and Revvity's revenue was at the 35th percentile of the peer group at the time of the analysis.
- The median market cap of the peer group at the time it was approved was $14,330 million and Revvity was at the 55th percentile of the peer group at the time of the analysis.
Stakeholder Impact
- Shareholders are asked to vote on key decisions regarding the company's direction and governance.
- Employees are impacted by the company's commitment to talent development, well-being, and diversity and inclusion.
- Customers may benefit from the company's focus on innovation and expanded product offerings.
Next Steps
- Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
- The company will hold its annual meeting of shareholders on April 23, 2024.
- The company is committed to submitting emission reduction targets for Science Based Targets initiative (SBTi) approval in the next 18 months.
Key Dates
| Date | Description |
|---|---|
| 2001 | Celera Genomics announced the first successful sequencing of the human genome. |
| 2001 | Dr. Frank Witney joined Revvity's Drug Discovery Tools division following Revvity's acquisition of Packard BioScience. |
| 2002 | Dr. Peter Barrett joined Atlas Venture. |
| June 20, 2002 | Revvity retained Deloitte & Touche LLP as its independent registered public accounting firm. |
| 2003 | Mr. Samuel R. Chapin was named Vice Chairman of Merrill Lynch & Co., Inc. |
| December 2008 | The Revvity, Inc. Deferred Compensation Plan was amended and restated. |
| December 2008 | The Plan was amended to bring it into documentary compliance with Section 409A. |
| January 1, 2009 | The Plan has operated in compliance with Section 409A. |
| 2009 | Revvity's 2009 Incentive Plan was approved by shareholders. |
| February 25, 2010 | The committee determined that future employment agreements issued to newly promoted or newly hired officers will provide 100% equity vesting upon termination following a change in control only if the officers employment is terminated within a specified period of time following the change in control. |
| July 30, 2010 | The committee determined that future employment agreements entered into with newly promoted or newly hired officers will not include a tax gross-up for excise taxes imposed under the Internal Revenue Code. |
| December 2010 | The committee amended our non-qualified deferred compensation plan to eliminate deferral elections from participants for plan years beginning January 1, 2011 or later. |
| January 1, 2011 | The committee amended our 401(k) Excess benefit to cease elective deferrals for plan years beginning January 1, 2011. |
| 2011 | Dr. Witney most recently served as President and Chief Executive Officer of Affymetrix, Inc. |
| 2012 | Dr. Prahlad Singh was General Manager of GE Healthcares Womens Health business. |
| 2012 | Dr. Peter Barrett joined the board of Revvity. |
| 2014 | Dr. Prahlad Singh joined Revvity as the President of our Diagnostics business. |
| 2014 | Revvity's 2009 Incentive Plan was reapproved by shareholders. |
| 2014 | Dr. Michelle McMurry-Heath joined Johnson & Johnson (J&J). |
| 2016 | Mr. Samuel R. Chapin retired from Bank of America Merrill Lynch. |
| 2016 | Dr. Frank Witney joined the board of Revvity. |
| 2016 | Mr. Michel Vounatsos joined Biogen Inc. |
| 2016 | Ms. Pascale Witz founded PWH Advisors. |
| July 2017 | Mr. Alexis P. Michas served as a director of Allied Motion Technologies, Inc. until July 2017. |
| 2017 | Mr. Michel Vounatsos served as the Chief Executive Officer of Biogen Inc. |
| 2017 | Ms. Pascale Witz joined the board of Revvity. |
| 2018 | Dr. Prahlad Singh was elected Executive Vice President. |
| 2018 | Dr. Sophie V. Vandebroek was Vice President, Emerging Technology Partnerships for IBM. |
| 2019 | Mr. Samuel R. Chapin served as a Senior Advisor to Rockefeller Capital Management. |
| 2019 | Dr. Prahlad Singh was elected President and Chief Operating Officer of the Company. |
| 2019 | Dr. Prahlad Singh was appointed to our board of directors. |
| 2019 | Revvity's 2019 Incentive Plan was approved by shareholders. |
| December 30, 2019 | Mr. Alexis P. Michas was named Non-Executive Chairman of the board. |
| December 30, 2019 | Dr. Prahlad Singh was elected President and Chief Executive Officer of Revvity. |
| 2019 | Mr. Michael A. Klobuchar was Senior Vice President, CFO and Head of Portfolio and Alliance Management for Merck Research Laboratories. |
| 2020 | Dr. Michelle McMurry-Heath served as President and Chief Executive Officer of the Biotechnology Innovation Organization. |
| 2020 | Mr. Michel Vounatsos joined the board of Revvity. |
| January 2021 | The committee approved a qualified officer retirement benefit. |
| 2021 | Dr. Sophie V. Vandebroek has served as founder and owner of Strategic Vision Ventures LLC. |
| 2021 | Mr. Michael A. Klobuchar has served as Executive Vice President and Chief Strategy Officer of Merck. |
| 2022 | Dr. Michelle McMurry-Heath joined the board of Revvity. |
| September 2022 | Mr. Maxwell Krakowiak was promoted to Senior Vice President and Chief Financial Officer. |
| 2023 | CIRCOR International, Inc. was formerly a director until 2023. |
| March 2023 | The divestiture of our Applied, Food and Enterprise Services businesses to New Mountain Capital. |
| May 15, 2023 | The annual grant date, which was the first day of the open trading window following our first quarter earnings release. |
| October 2, 2023 | The committee approved a new clawback policy and adopted revisions to the Global ICP plan recoupment provision. |
| October 26, 2023 | Our board approved changes to director compensation that will go into effect on April 23, 2024. |
| February 26, 2024 | The record date for determining shareholders entitled to receive notice of, and to vote their shares at, the meeting. |
| February 2024 | Mr. Michael A. Klobuchar and Dr. Sophie V. Vandebroek were each elected to serve as a director beginning in February 2024. |
| March 13, 2024 | The date of this proxy statement. |
| April 23, 2024 | The annual meeting of the shareholders of Revvity, Inc. will be held via a live webcast. |
| April 23, 2024 | Changes to director compensation that will go into effect on April 23, 2024, the date of our 2024 annual meeting of shareholders. |
Keywords
Revvity, shareholders, annual meeting, directors, executive compensation, Deloitte & Touche LLP, ESG, corporate governance, proxy statement
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.